|Table of Contents|

CT characterization of immune checkpoint inhibitor-related pneumonitis and literature review

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 19
Page:
3658-3662
Research Field:
Publishing date:

Info

Title:
CT characterization of immune checkpoint inhibitor-related pneumonitis and literature review
Author(s):
XU Yanqiu1; YANG Xiaoguang2; XU Hongwei3; ZHAO Zhenyuan1; LIU Aishi4; WANG Dapeng4
1.First Clinical Medical College of Inner Mongolia Medical University，Inner Mongolia Hohhot 010050,China;2.Medical Imaging Department，Hohhot First Hospital,Inner Mongolia Hohhot 010030,China;3.The Ninth People's Hospital of Zhengzhou，Henan Zhengzhou 450053,China;4.Department of Imaging Diagnosis，Affiliated Hospital of Inner Mongolia Medical University，Inner Mongolia Hohhot 010050,China.
Keywords:
immune checkpoint inhibitor; interstitial lung disease; computed tomography
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.19.024
Abstract:
Objective:To initially investigate the features and changes of chest CT in patients with checkpoint inhibitor-related pneumonitis（CIP) and to review the relevant literature.Methods:Retrospective analysis was performed to compare the CT images of 5 patients diagnosed with CIP and to summarize the preliminary CIP imaging features.All five patients were male and developed clinical manifestations such as shortness of breath，palpitations，cough，chest tightness，diarrhea，Velcro rales and bone marrow suppression at different times after being treated with immune checkpoint inhibitors after the diagnosis of lung cancer.CT signs in the chest included ground glass opacity，consolidation shadows，reticular shadows，honeycomb shadows，fibro stripe，traction bronchiectasis and nodular shadows，symmetrically or asymmetrically distributed.Results:CIP images mainly show diverse and polymorphic lesions in the lungs with mainly interstitial changes，and the distribution is mainly in the outer bands of the lung fields either bilaterally or unilaterally，and after corticosteroid treatment，the clinical symptoms and signs all improve and the imaging manifestations all absorb.Conclusion:The imaging signs of CIP have different manifestations，but CT can objectively and clearly show the changes of interstitial lung disease，which is important for the diagnosis and efficacy evaluation of CIP patients.

References:

［1］WANG HP，ZHAO YW，ZHANG XT，et al.Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis：A single-institution retrospective study［J］.Cancer Medicine,2021,10(1):188-198.
［2］SURESH K，PSOTER KJ，VOONG KR，et al.Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy［J］.Journal of Thoracic Oncology,2019,14(3):494-502.
［3］JOHKOH T，LEE KS，NISHINO M，et al.Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors：A position paper from the Fleischner Society［J］.Radiology,2021,298(3):550-566.
［4］YIN JQ，WU YJ，YANG X，et al.Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy in non-small-cell lung cancer：Occurrence and mechanism［J］.Frontiers in Immunology,2022,13:830631.
［5］FREITAS HMP，MAN ANO AD，RODRIGUES RS，et al.Niemann-pick disease type B：HRCT assessment of pulmonary involvement［J］.Jornal Brasileiro de Pneumologia,2017,43(6):451-455.
［6］FU FF，LOU JH，XI DY，et al.Chest computed tomography findings of coronavirus disease 2019（COVID-19) pneumonia［J］.European Radiology,2020,30(10):5489-5498.
［7］WANG WX，WANG Q，XU CW，et al.Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor［J］.Thoracic Cancer,2022,13(23):3420-3430.
［8］ZHANG M，FAN Y，NIE LG，et al.Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases：A systematic review and Meta-analysis［J］.Chest,2022,161(6):1675-1686.
［9］POSTOW MA，SIDLOW R，HELLMANN MD.Immune-related adverse events associated with immune checkpoint blockade［J］.The New England Journal of Medicine,2018,378(2):158-168.
［10］DELAUNAY M，CADRANEL J，LUSQUE A，et al.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients［J］.The European Respiratory Journal,2017,50(2):1700050.
［11］NOBASHI TW，NISHIMOTO Y，KAWATA Y，et al.Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers［J］.The British Journal of Radiology,2020,93(1115):20200409.
［12］ZHANG Q，ZHAO SJ，WANG SH，et al.Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis［J］.Chinese Journal of Oncology,2023,45(2):182-187.
［13］FRAGKOU P，SOULI M，THEOCHARI M，et al.A case of organizing pneumonia（OP) associated with pembrolizumab［J］.Drug Target Insights,2016,10:9-12.
［14］PANG L，XIE M，MA XD，et al.Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer［J］.BMC Cancer,2023,23(1):203.
［15］NAIDOO J，WANG X，WOO KM，et al.Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy［J］.Journal of Clinical Oncology,2017,35(7):709-717.
［16］QIU Q，XING L，WANG Y，et al.Development and validation of a radiomics nomogram using computed tomography for differentiating immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis for patients with non-small cell lung cancer［J］.Frontiers in Immunology,2022,13:870842.
［17］BLANCHARD A，BOUCHARD N.Pembrolizumab-induced obstructive bronchiolitis in a patient with stage Ⅳ non-small-cell lung cancer［J］.Current Oncology（Toronto，Ont.),2019,26(4):e571-e573.
［18］SHANKAR B，ZHANG JJ，NAQASH AR，et al.Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer［J］.JAMA Oncology,2020,6(12):1952-1956.

Memo

Memo:
内蒙古自治区科技计划项目（编号：2020GG0122）
Last Update: 2023-08-31